Oct 6 (Reuters) – * EISAI AND BIOGEN ANNOUNCE U.S. AVAILABILITY OF LEQEMBI® IQLIK™ (LECANEMAB-IRMB) SUBCUTANEOUS INJECTION MAINTENANCE DOSE FOR TREATMENT OF EARLY ALZHEIMER’S DISEASE Source text:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Adwitiya Srivastava (Reuters) -Australia's corporate regulator on Tuesday approved Cboe Global Markets' application to…
Oct 6 (Reuters) - Coty Inc: * COTY INC. PRICES $900.0 MILLION OF SENIOR NOTES…
* Three-judge panel declared law unconstitutional * Republicans sought more prominent expressions of faith *…
(Reuters) -Rio Tinto said on Tuesday it along with its joint venture partners Mitsui Iron…
(Adds details from the report, background throughout) Oct 6 (Reuters) - A fire that broke…
A LaLiga match between Barcelona and Villarreal can be played in Miami this December after…